skip to Main Content

Immune checkpoints in liver tumours and beyond

This session runs in parallel to the grand rounds on Friday and offers a basic alternative to scientists.

Emerging clinical data attest to the efficacy of triggering tumor-specific immune responses for the treatment of hepatocellular carcinoma, and this therapy also holds promise for the treatment of biliary tract cancers. On the other hand, adaptive immune dysfunction involving mechanisms overlapping with those involved in the inhibition of tumor-associated immune responses may also participate in the complications of acute liver failure.